In a statement, the Danish company said the move would help to address "access barriers" to the medicines and "make it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy and Ozempic in the way that best fits their lives." There's little doubt that one of the reasons for the move will be to try to keep pace with arch-rival Eli Lilly in the market for incretin-based therapies for obesity and T2D, particularly the strong growth of Lilly's dual GIP/GLP-1 agonist tirzepatide, whose growth rate is outstripping Novo Nordisk's products
Neuromuscul Disord 30(6):492502 Giovarelli M, Zecchini S, Casati SR, Lociuro L, Gjana O, Mollica L et al (2025) The SIRT1 activator SRT2104 exerts exercise mimetic effects and promotes Duchenne muscular dystrophy recovery
There are many ways to take care of your heart and reduce the risk of heart disease when living with diabetes cholesterol lowering medications (statins), smoking cessation, and aerobic exercise are especially important
If you prefer to pay monthly and cancel anytime, clinics like Mochi Health offer more flexibility
